Worth reading
66In focus
Scored from 1 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
104600
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of the 25th Series Stock Acquisition Rights through a third-party allotment, with provisions for exercise price adjustments (this disclosure reports the monthly exercise status)
発行・処分する株式数104,600Shares
Number of shares delivered during the month under review: 104,600 new shares
発行済株式総数
Exercise ratio relating to exercise restrictions: 0.30% (104,600 shares delivered across all series / 34,666,419 listed shares outstanding at the time payment was made for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
With an Exercise Price Adjustment Clause. The exercise prices during the month under review were ¥209.52, ¥215.34, ¥219.22, ¥226.01, ¥207.58, ¥214.37, ¥218.25, ¥226.98, ¥217.28, ¥212.43, ¥211.46, ¥205.64, ¥209.52, ¥199.82, ¥194.97 and ¥201.76.
Number of Stock Acquisition Rights
Total issued: 86,000 rights; exercised during the month under review: 1,046 rights; unexercised as of the end of the preceding month: 39,472 rights; unexercised as of the end of the month under review: 38,426 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Timing 8 December 2025 / Type Issuance of Series 25 Stock Acquisition Rights (with Exercise Price Adjustment Clause) through a third-party allotment / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of the 25th Series Stock Acquisition Rights through a third-party allotment, with provisions for exercise price adjustments (this disclosure reports the monthly exercise status) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month under review: 104,600 new shares |
| Dilution Rate | Exercise ratio relating to exercise restrictions: 0.30% (104,600 shares delivered across all series / 34,666,419 listed shares outstanding at the time payment was made for the issuance) |
| Exercise price | With an Exercise Price Adjustment Clause. The exercise prices during the month under review were ¥209.52, ¥215.34, ¥219.22, ¥226.01, ¥207.58, ¥214.37, ¥218.25, ¥226.98, ¥217.28, ¥212.43, ¥211.46, ¥205.64, ¥209.52, ¥199.82, ¥194.97 and ¥201.76. |
| Number of Stock Acquisition Rights | Total issued: 86,000 rights; exercised during the month under review: 1,046 rights; unexercised as of the end of the preceding month: 39,472 rights; unexercised as of the end of the month under review: 38,426 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Timing 8 December 2025 / Type Issuance of Series 25 Stock Acquisition Rights (with Exercise Price Adjustment Clause) through a third-party allotment / Amount Not disclosed |
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status for July 2026 of the Series 25 Stock Acquisition Rights issued on 8 December 2025.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.